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R904In the late 1990s, when the human
genome project was beginning to
look like a realistic endeavour,
only to be challenged by the
competing bid from entrepreneur
and shotgun sequencing pioneer
Craig Venter, the competition
between a publicly funded
sequencing effort and a private
one raised the issue of who would
own the genome data, and
whether parts of it would be
protected by patents. As genomic
research moved on at lightning
pace, this debate was somehow
left behind. Now for the first time,
two MIT researchers have
‘mapped’ patents of human genes
onto the genome, to present an
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A new study has mapped human
genes to patents and finds just
how many are involved in
commercial interests. Michael
Gross reports.overview of the intellectual
property situation in human
genomics. 
Kyle Jensen and Fiona Murray
have fed information from US
patent databases into standard
bioinformatics search tools such
as BLAST, in order to establish
which genes are covered by one
or several patents, and whether
there are any patterns in the
patenting activity. They discovered
that, of the 23,688 human genes
listed in the databases they used,
4,382 or 18.5 per cent were
claimed as intellectual property by
at least one US patent (Science
(2005) 310, 239). 
So who owns the patent rights
to nearly a fifth of our genome?
The researchers identified 1,156
different patent holders, although
this number may be reduced by
mergers, acquisitions, and naming
variations. Almost two-thirds of
the patents are held by private
companies. The leader of the pack
seems to be the firm Incyte, which
holds rights over more than 2,000
different human genes. Most of
these patents are related to the
use of gene sequences in DNA
microarrays. When mapped to the genome,
the patents show a predictable
clustering on medically relevant
genes. The two hottest of the
intellectual property hotspots are
BMP7, which stimulates bone
growth, and the tumor suppressor
CDKN2A, each covered by 20
patents. An additional ten genes
are claimed by ten or more
different patents, and over 100
genes are covered by five or more.
So far, it is unclear, the authors
say, “whether current practice in
patent examination has allowed
multiple conflicting patents on the
same gene.”
Ever since genome sequencing
began, there have been debates
about the benefits and risks of
gene patents. Many in the biotech
industry will defend the practice,
claiming that the patent protection
provides incentive for product
development. With the new study
there is now a foundation to
investigate in more detail the
effects the patenting situation has
had and may have in the future.
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